SMMT at $10.9B: Ivonescimab PDUFA Is a Coin Flip

Summit Therapeutics (SMMT) closed Friday at $13.66, down 8.8% from its July 22 close of $14.98 when the company released updated overall survival data. The stock now trades near its 52-week low of $12.55 and 56% below its 52-week high of $30.98. With a $10.9 billion market cap and exactly one drug in FDA review, Summit is the most concentrated binary bet in biotech right now.

I think the market has this one about right. The updated HARMONi data is encouraging but not conclusive. The November 14 PDUFA is a coin flip, and $13.66 prices in roughly 50% approval odds. Here is why.

The HARMONi Data: Good, Not Great

Summit’s BLA rests on the Phase 3 HARMONi trial, which evaluated ivonescimab plus chemotherapy versus chemotherapy alone in 438 patients with EGFR-mutant non-small cell lung cancer who had progressed after third-generation EGFR TKI therapy.

The progression-free survival data is strong. Ivonescimab achieved a PFS hazard ratio of 0.46 (95% CI: 0.34, 0.62; P < .001), cutting the risk of disease progression or death by 54%. Median PFS was 7.1 months versus 4.8 months for chemotherapy alone. The objective response rate was 50.6% versus 35.4%. These are clinically meaningful numbers by any standard.

The overall survival data is where the story gets complicated. The updated July 2026 analysis showed an OS hazard ratio of 0.76 in both the global ITT population and the Western patient subgroup. That translates to a 24% reduction in the risk of death. Median OS was 16.8 months for ivonescimab versus 14.0 months for chemotherapy alone.

Here is the problem: HARMONi missed its primary overall survival endpoint in the initial analysis. The FDA had explicitly requested statistically significant OS data to support the filing. Summit submitted the BLA anyway, framing the miss as a technical failure rather than a drug efficacy problem. This updated analysis strengthens the case, but it does not change the fact that the original primary endpoint was not met. The FDA has historically been hostile to applications where the primary endpoint failed, regardless of secondary endpoint trends.

The Western patient convergence matters because ivonescimab originated in China, developed by Akeso. The FDA scrutinizes regional subgroup data heavily for foreign-origin drugs. A hazard ratio of 0.76 in Western patients matching the ITT population removes one objection. But the missed primary endpoint remains the central regulatory risk.

HARMONi-2: The Bigger Opportunity Nobody Is Talking About

While the BLA focuses on the post-TKI EGFR-mutant setting, the real prize is first-line treatment. The Phase 3 HARMONi-2 trial compared ivonescimab monotherapy head-to-head against pembrolizumab (Keytruda) in PD-L1 positive advanced NSCLC. The results were striking: ivonescimab achieved a PFS hazard ratio of 0.51 (95% CI: 0.38, 0.69; P < .0001), a 49% reduction in the risk of disease progression or death versus Keytruda. Median PFS was 11.14 months versus 5.82 months.

This was the first randomized Phase 3 study to demonstrate superiority over pembrolizumab in frontline NSCLC. If that result holds up in a global confirmatory trial (HARMONi-3 is enrolling), ivonescimab could challenge Keytruda’s $25 billion annual franchise. But HARMONi-2 was conducted in China by Akeso, and the FDA has not accepted it as part of the current BLA. The first-line opportunity is a 2028 story at the earliest.

Competitive Picture: David versus Goliath

Ivonescimab would be the first PD-1/VEGF bispecific antibody to reach the US market. The mechanism is distinct: it blocks PD-1 (to activate immune response) and VEGF (to cut off tumor blood supply) with a single molecule. The theoretical advantage over Keytruda is that you get dual pathway blockade without the toxicity of combining two separate drugs.

The commercial question is whether Summit can compete with Merck. Keytruda generated $25 billion in 2025 revenue and has a 40% market share in first-line NSCLC. Merck has 30,000 oncology sales reps, established relationships with every major cancer center, and a pricing power advantage. Summit has 265 employees.

The most relevant comp here is not Merck. It is Gilead’s Trodelvy, another challenger that tried to compete with Keytruda in a niche NSCLC subpopulation and struggled commercially despite having strong trial data. Gilead has 18,000 employees and $28 billion in revenue. Summit has neither the balance sheet nor the commercial infrastructure to match Gilead, let alone Merck.

For broader context on how myeloma drugs compete in crowded oncology markets, our coverage of J&J’s Tecvayli plus Talvey Phase 3 illustrates how even large pharma with multiple oncology products faces commercial headwinds.

Valuation: $10.9 Billion for a Coin Flip

At $13.66 per share and 776 million shares outstanding, Summit’s market cap is $10.9 billion. The company has $598.7 million in cash as of March 31, 2026, down from $713.4 million at December 31, 2025. That is a quarterly burn rate of approximately $115 million, giving Summit roughly 5 quarters of runway. R&D expenses were up 190.8% year-over-year to $79.4M as the company scales for a potential launch.

The median analyst price target is $29, with 16 of 20 analysts rating the stock a Buy. The high estimate is $45. If the FDA approves ivonescimab on November 14, the stock could gap to $25 or higher on the approval alone, with further upside as the market prices in the commercial launch. If the FDA issues a Complete Response Letter, the stock could fall to $6 to $8, a 40 to 55% decline.

Let me do the math. At $13.66, the market is pricing in approximately 50% approval odds. If approval sends the stock to $25 (a $11.34 gain) and rejection sends it to $7 (a $6.66 loss), the expected value is approximately $2.34 per share, or 17% upside. That is a thin margin for a binary bet with a missed primary endpoint.

Compare Summit to a revenue-generating comp in the same space. Gilead trades at $11.4 billion in oncology revenue alone and has a diversified pipeline across HIV, oncology, and inflammation. Summit’s entire $10.9 billion market cap rests on one drug with one missed primary endpoint. Gilead’s oncology franchise alone is worth more than Summit’s entire enterprise value, and Gilead has 20 approved products.

Risks

The primary risk is the missed OS endpoint. The FDA can approve a drug based on PFS alone, but the agency’s internal guidelines emphasize that PFS benefits should translate to OS benefits in confirmatory data. HARMONi’s OS trend is positive (HR 0.76) but not statistically significant. An advisory committee meeting before November 14 would signal regulatory concern. No adcom request so far is a positive sign, but given the missed primary endpoint, an adcom remains possible.

The secondary risk is cash. At $115 million quarterly burn, Summit has approximately 5 quarters of runway. A CRL in November would require a secondary offering at a depressed valuation, diluting shareholders by 30 to 40%.

Verdict

Summit at $13.66 is a Speculative Hold. The HARMONi-2 head-to-head data against Keytruda is genuinely impressive, and the PFS data in the EGFR-mutant setting is strong. But the missed primary OS endpoint is a real regulatory risk, and $10.9 billion is a lot of money for a company with no revenue and one drug in review. I would not short this stock; the HARMONi-2 data is too good and the short interest is too high. But I would not buy it either, not when the expected value of the binary bet is only 17% upside against a 50% chance of a 50% decline.

For investors who want exposure to the ivonescimab thesis without the binary risk, Akeso (1559.HK), the Chinese originator, trades at a fraction of Summit’s valuation and already has ivonescimab approved in China. The discount reflects the China premium, but the drug is the same molecule. For more on our initial coverage of Summit’s ivonescimab OS data and the PDUFA timeline, see our summit ivonescimab OS data and PDUFA November coverage.